The perhaps most important event during the fourth quarter was the listing on Aktietorget on July 13th and the associated listing issue, which was subscribed to approximately 18 MSEK, corresponding to a subscription quota of approximately 72 percent. The company's main owner, Diamyd Medical AB and Chairman Anders Essen-Möller contributed sizeable amounts. NextCell announced at the end of July 2017 that the company applied to the Medical Products Agency to conduct a clinical trial with the company's drug candidate ProTrans™ on type 1 diabetes patients. The application was granted on October 17 (post-period).

"During the fiscal year, the company's financial position has been strengthened and the cash balance as of August 31st, after a large payment for the GMP-Study Drug, amounted to approximately SEK 16 million. The listing on Aktietorget and the subsequent Medical Products Agency approved clinical trial application indicate that the company is moving forward, from strength to strength," says CFO Leo Groenewegen.

"I look forward to next year with clinical trial on type 1 diabetes patients, and hope that Cellaviva out service family saving of stem cells cord blood and tissue will develop well," says CEO Mathias Svahn.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on October 31, 2017.